Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Official Title

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Summary:

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumours.

Trial Description

Primary Outcome:

  • The number of subjects with adverse events/serious adverse events
  • The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
Secondary Outcome:
  • Percentage change in target lesion
  • Objective Response Rate
  • Duration of response
  • Progression Free Survival
  • Time to response
  • Effects of AZD5305 on Ph2AX (Ser139) PD biomarker
  • Module 1: Area under curve (AUC)
  • Module 1: Maximum plasma concentration of the drug (Cmax)
  • Module 1: The time taken to reach the maximum concentration (Tmax)
  • Module 2: Area under curve (AUC)
  • Module 2: Maximum plasma concentration of the drug (Cmax)
  • Module 2: The time taken to reach the maximum concentration (Tmax)
  • Module 3: Area under curve (AUC)
  • Module 3: Maximum plasma concentration of the drug (Cmax)
  • Module 3: The time taken to reach the maximum concentration (Tmax)
This study is a Phase I/IIa modular, open-label, multi-centre study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society